Cocrystal Pharma Inc（COCP）财务数据COCPCocrystal Pharma Inc

Evaluating the bottom line, Cocrystal Pharma Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3032.38%, while the net margin is -3013.33%. These profitability ratios, combined with a Return on Equity (ROE) of -311.68%, provide a clear picture of how effectively COCP converts its operational activities into shareholder value.

In the context of the broader market, COCP competes directly with industry leaders such as CANF and NEUP. With a market capitalization of $22.35M, it holds a leading position in the sector. When comparing efficiency, COCP's gross margin of 100.00% stands against CANF's 100.00% and NEUP's N/A. Such benchmarking helps identify whether Cocrystal Pharma Inc is trading at a premium or discount relative to its financial performance.

Cocrystal Pharma has reported zero revenue in the last five quarters, with significant net losses, including a loss of $3.16 million in Q2 2026. The gross margin is currently at 100% due to minimal revenue, but the overall financial health is concerning with a current ratio of 1.24, indicating potential liquidity issues.